The recent approval of Yeztugo, a twice-yearly injectable medication for Human Immunodeficiency Virus (HIV) prevention, has sparked mixed reactions from experts.
While hailing the breakthrough as a significant advancement in HIV prevention, they warn that the high cost could limit access to millions of vulnerable people worldwide.
“This is a breakthrough moment. The approval of Lenacapavir is a testament to decades of public investment, scientific excellence, and the contributions of trial participants and communities“, said Winnie Byanyima, Executive Director of UNAIDS.
However, she criticized the pricing, saying, “It is beyond comprehension how Gilead can justify a price of $28,218.
“If this game-changing medicine remains unaffordable, it will change nothing.”
A renowned virologist, Prof. Oyewale Tomori, emphasized the need for African countries to invest in local research and pharmaceutical development to avoid disparities in access.
“Until African countries begin to produce and manufacture their vaccines and treatments, such disparities in access are to be expected,” he said.
Experts estimate that generic Lenacapavir could be produced for as little as $35-46 per person per year, making it comparable to existing products.
“It’s not enough to have the science, we need it in the hands of those who need it most,” said Jeremiah Johnson, Executive Director of PrEP4All.
